title: Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
abstract: Prostate specific antigen has been extensively studied and represents the most common biomarker across the spectrum of prostate cancer. Circulating tumor cells are a more recent method for monitoring patients with metastatic prostate cancer and have shown great promise in predicting outcomes. We review the prognostic capabilities of these markers to determine if circulating tumor cells should unseat prostate specific antigen as the test of choice in prostate cancer.
authors.affiliation: Institute of Urology, Keck Medical Center of USC, University of Southern California, Los Angeles, CA, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Hu
authors.forename: Amir
authors.initials: A
authors.lastname: Goldkorn
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating / Q000378:metabolism*; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D015996:Survival Rate / Q000639:trends
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
keywords: PSA; circulating tumor cells; prognosis; prostate cancer; survival